164 related articles for article (PubMed ID: 20438839)
21. Fate of paclitaxel lipid nanocapsules in intestinal mucus in view of their oral delivery.
Groo AC; Saulnier P; Gimel JC; Gravier J; Ailhas C; Benoit JP; Lagarce F
Int J Nanomedicine; 2013; 8():4291-302. PubMed ID: 24235827
[TBL] [Abstract][Full Text] [Related]
22. In vivo evaluation of lipid nanocapsules as a promising colloidal carrier for paclitaxel.
Lacoeuille F; Hindre F; Moal F; Roux J; Passirani C; Couturier O; Cales P; Le Jeune JJ; Lamprecht A; Benoit JP
Int J Pharm; 2007 Nov; 344(1-2):143-9. PubMed ID: 17646066
[TBL] [Abstract][Full Text] [Related]
23. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo.
Varma MV; Panchagnula R
Eur J Pharm Sci; 2005; 25(4-5):445-53. PubMed ID: 15890503
[TBL] [Abstract][Full Text] [Related]
24. Modulation of drug transport by selected flavonoids: Involvement of P-gp and OCT?
Ofer M; Wolffram S; Koggel A; Spahn-Langguth H; Langguth P
Eur J Pharm Sci; 2005 Jun; 25(2-3):263-71. PubMed ID: 15911222
[TBL] [Abstract][Full Text] [Related]
25. Effects of lipid vehicle and P-glycoprotein inhibition on the mesenteric lymphatic transport of paclitaxel in unconscious, lymph duct-cannulated rats.
Cai Q; Deng X; Li Z; An D; Shen T; Zhong M
Drug Deliv; 2016; 23(1):147-53. PubMed ID: 24786483
[TBL] [Abstract][Full Text] [Related]
26. Drug penetration model of vinblastine-treated Caco-2 cultures.
Hellinger E; Bakk ML; Pócza P; Tihanyi K; Vastag M
Eur J Pharm Sci; 2010 Sep; 41(1):96-106. PubMed ID: 20595016
[TBL] [Abstract][Full Text] [Related]
27. Utility of 96 well Caco-2 cell system for increased throughput of P-gp screening in drug discovery.
Balimane PV; Patel K; Marino A; Chong S
Eur J Pharm Biopharm; 2004 Jul; 58(1):99-105. PubMed ID: 15207543
[TBL] [Abstract][Full Text] [Related]
28. Taxol transport by human intestinal epithelial Caco-2 cells.
Walle UK; Walle T
Drug Metab Dispos; 1998 Apr; 26(4):343-6. PubMed ID: 9531522
[TBL] [Abstract][Full Text] [Related]
29. Stereoselective transport and uptake of propranolol across human intestinal Caco-2 cell monolayers.
Wang Y; Cao J; Wang X; Zeng S
Chirality; 2010 Mar; 22(3):361-8. PubMed ID: 19575464
[TBL] [Abstract][Full Text] [Related]
30. Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus.
Arima H; Yunomae K; Hirayama F; Uekama K
J Pharmacol Exp Ther; 2001 May; 297(2):547-55. PubMed ID: 11303042
[TBL] [Abstract][Full Text] [Related]
31. Stereoselective and multiple carrier-mediated transport of cetirizine across Caco-2 cell monolayers with potential drug interaction.
He Y; Liu Y; Zeng S
Chirality; 2010 Jul; 22(7):684-92. PubMed ID: 20014242
[TBL] [Abstract][Full Text] [Related]
32. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.
Zhan C; Gu B; Xie C; Li J; Liu Y; Lu W
J Control Release; 2010 Apr; 143(1):136-42. PubMed ID: 20056123
[TBL] [Abstract][Full Text] [Related]
33. The ethanol metabolite acetaldehyde increases paracellular drug permeability in vitro and oral bioavailability in vivo.
Fisher SJ; Swaan PW; Eddington ND
J Pharmacol Exp Ther; 2010 Jan; 332(1):326-33. PubMed ID: 19820208
[TBL] [Abstract][Full Text] [Related]
34. Caco-2 cell methodology and inhibition of the P-glycoprotein transport of digoxin by Aloe vera juice.
Djuv A; Nilsen OG
Phytother Res; 2008 Dec; 22(12):1623-8. PubMed ID: 19003953
[TBL] [Abstract][Full Text] [Related]
35. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules.
Peltier S; Oger JM; Lagarce F; Couet W; Benoît JP
Pharm Res; 2006 Jun; 23(6):1243-50. PubMed ID: 16715372
[TBL] [Abstract][Full Text] [Related]
36. Novel self-assembling PEG-p-(CL-co-TMC) polymeric micelles as safe and effective delivery system for paclitaxel.
Danhier F; Magotteaux N; Ucakar B; Lecouturier N; Brewster M; Préat V
Eur J Pharm Biopharm; 2009 Oct; 73(2):230-8. PubMed ID: 19577643
[TBL] [Abstract][Full Text] [Related]
37. N-Deoxycholic acid-N,O-hydroxyethyl Chitosan with a Sulfhydryl Modification To Enhance the Oral Absorptive Efficiency of Paclitaxel.
Yu Y; Huo M; Fu Y; Xu W; Cai H; Yao L; Chen Q; Mu Y; Zhou J; Yin T
Mol Pharm; 2017 Dec; 14(12):4539-4550. PubMed ID: 29058910
[TBL] [Abstract][Full Text] [Related]
38. Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier.
Beloqui A; Solinís MÁ; Gascón AR; del Pozo-Rodríguez A; des Rieux A; Préat V
J Control Release; 2013 Mar; 166(2):115-23. PubMed ID: 23266764
[TBL] [Abstract][Full Text] [Related]
39. N-mercapto acetyl-N'-octyl-O, N″-glycol chitosan as an efficiency oral delivery system of paclitaxel.
Huo M; Fu Y; Liu Y; Chen Q; Mu Y; Zhou J; Li L; Xu W; Yin T
Carbohydr Polym; 2018 Feb; 181():477-488. PubMed ID: 29253998
[TBL] [Abstract][Full Text] [Related]
40. Novel double coated nanocapsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug.
Nassar T; Rom A; Nyska A; Benita S
J Control Release; 2009 Jan; 133(1):77-84. PubMed ID: 18822327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
